History
FDA Breakthrough Device Designation
Virtuoso Surgical Robotic System receives FDA breakthrough device designation for bladder lesion removal via en block excision, positions company at forefront of early diagnosis and bladder cancer care.
First-In-Human Bladder Cancer Removal Cases
Virtuoso Surgical Robotic System facilites endoscopic bladder lesion excisions using advanced en bloc technique that removes lesion intact vs. piecemeal. Groundbreaking cases performed by Dr. Jeremy Teoh, a world-renowned bladder cancer surgeon and researcher.
Investor Showcase
Virtuoso unveils its newly designed system, and CEO and Chief Medical Officer Duke Herrell performs a live demonstration.
Successful Cadaver Experiments for Central Airway Obstruction Removal
Virtuoso completes 30 experiments in both male and female cadavers on removing tumors obstructing the central airway.
Unveiling of Virtuoso at the American Urological Association Conference
Virtuoso debuts our robotic system publicly to the medical community at our booth at the AUA annual meeting.
First Live Animal Experiments
Virtuoso completes first experiments in live animals. These experiments demonstrated successful tissue resection from the animal’s uterus.
First Cadaver TURBT Experiments
Virtuoso completes successful experiments in a cadaver bladder, simulating the Transurethral Resection of Bladder Tumor (TURBT) procedure. Virtuoso also completes successful prostate tissue resections in a cadaver at the same time.
First Ex Vivo Animal Uterine Surgery
Virtuoso performs successful experiments in an ex vivo uterine animal tissue model. These experiments are subsequently published in the Journal of Minimally Invasive Gynecology and nominated for a best video award at the American Association of Gynecologic Laparoscopists annual meeting.
Initial Public Offering of Preferred Shares
Initial Public Offering to advance Virtuoso Surgical’s groundbreaking robotic system for endoscopic surgery becomes effective after review by the United States Securities and Exchange Commission and the Financial Industry Regulatory Authority.
Virtuoso Receives SBIR Phase II Grant
Virtuoso Surgical receives a grant from the National Heart, Lung, and Blood Institute to further study the use of Virtuoso's technology to treat central airway obstructions.
Virtuoso Founders Present at American Urologic Association
Robert Webster and Duke Herrell visit the American Urologic Association's Annual Meeting to present about Virtuoso's potential treatment for benign prostatic hyperplasia.
Virtuoso Receives STTR Phase I Grant
Virtuoso Surgical receives an STTR award from the National Heart, Lung, and Blood Institute. The award will fund the application of Virtuoso's technology to treat central airway obstructions.
Virtuoso Receives SBIR Phase II Grant
Virtuoso Surgical receives a Notice of Award from the National Institute of Biomedical Imaging and Bioengineering. The NIH award is expected to fund prototype development, testing, and regulatory approval efforts for a two-year period.
Virtuoso Begins Formal Operations
Virtuoso Surgical begins formal operations and opens its engineering offices and laboratory in Nashville, Tennessee, for development of its endoscopic surgical device.
Virtuoso Surgical, Inc. Founded
Virtuoso Surgical, Inc. is incorporated by Dr. Webster, Dr. Herrell, and Dr. Hendrick to commercialize a surgical device using concentric tube technology.